OLMA

SEC source: 0001415889-23-009406 · form4-06072023_090601.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,053,714

F1 · price: The weighted average sale price for the transaction reported was $6.045 and the range of prices were between $5.96 and $6.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · balance_after: Includes 7,568 shares acquired under the issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-23-006359 · form4-04072023_040409.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 396,197

F1 · price: The weighted average purchase price for the transaction reported was $3.4173, and the range of prices were between $3.375 and $3.42. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 5,000 shares acquired under the issuer's Employee Stock Purchase Plan.

SEC source: 0001209191-23-006291 · doc4.xml · derivative · entry 1

Moriarty John B · CIK 0001564621 · EVP, Ch. Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006286 · doc4.xml · derivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006295 · doc4.xml · derivative · entry 1

Zojwalla Naseem · CIK 0001905871 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006289 · doc4.xml · derivative · entry 1

Myles David C. · CIK 0001831216 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006279 · doc4.xml · derivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006285 · doc4.xml · derivative · entry 1

Horn Kinney · CIK 0001831215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001209191-23-006284 · doc4.xml · derivative · entry 1

Bohen Sean · CIK 0001831218 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-009880 · form4-09222022_030957.xml · nonDerivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,279

F1 · price: The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-22-009915 · form4a-09232022_020934.xml · nonDerivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,279

F1 · kind: This amendment is being filed solely to correct the transaction code in column 3 of Table I from code "A" to code "P".

F2 · price: The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

F3 · balance_after: Includes 5 shares acquired under the issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-22-009373 · form4-09062022_010928.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,197

F1 · price: The weighted average purchase price for the transaction reported was $3.59, and the range of prices were between $3.53 and $3.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 2,517 shares acquired under the issuer's Employee Stock Purchase Plan.

SEC source: 0001415889-22-006959 · form4a-06272022_020613.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006964 · form4a-06272022_020650.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006962 · form4a-06272022_020617.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006963 · form4a-06272022_020620.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006965 · form4a-06272022_020657.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006961 · form4a-06272022_020606.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006960 · form4a-06272022_020605.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-16

F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006783 · form4-06172022_040617.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006786 · form4-06172022_040650.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006781 · form4-06172022_040613.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006784 · form4-06172022_040644.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006787 · form4-06172022_040602.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006785 · form4-06172022_040645.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-22-006782 · form4-06172022_040626.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000921895-22-001989 · form407422010_06142022.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,906,659

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-22-001989 · form407422010_06142022.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,913,676

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001415889-22-002936 · form4-03142022_010315.xml · derivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,785

Underlying: Common Stock · 5,253 shares

Expires 2030-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-002936 · form4-03142022_010315.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001415889-22-002936 · form4-03142022_010315.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-001314 · form4-02142022_020227.xml · derivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,038

Underlying: Common Stock · 5,251 shares

Expires 2030-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001314 · form4-02142022_020227.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2 · price: The weighted average sale price for the transaction reported was $5.46, and the range of prices were between $5.14 and $5.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-22-001314 · form4-02142022_020227.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-001060 · form4-02032022_040213.xml · derivative · entry 1

Kushner Peter J. · CIK 0001831217 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,750

Underlying: Common Stock · 61,750 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001057 · form4-02032022_040246.xml · derivative · entry 1

Moriarty John B · CIK 0001564621 · EVP, CH. LEGAL OFFICER & SEC.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,250

Underlying: Common Stock · 166,250 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001056 · form4-02032022_040213.xml · derivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,000

Underlying: Common Stock · 247,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001061 · form4-02032022_040238.xml · derivative · entry 1

Myles David C. · CIK 0001831216 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,750

Underlying: Common Stock · 118,750 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001059 · form4-02032022_040230.xml · derivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,500

Underlying: Common Stock · 104,500 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001058 · form4-02032022_040207.xml · derivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,000

Underlying: Common Stock · 133,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001055 · form4-02032022_040258.xml · derivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 812,250

Underlying: Common Stock · 812,250 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-001054 · form4-02032022_030247.xml · derivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-000480 · form4-01112022_050141.xml · derivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,289

Underlying: Common Stock · 5,251 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-22-000480 · form4-01112022_050141.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,458

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2 · price: The weighted average sale price for the transaction reported was $6.85, and the range of prices were between $6.60 and $7.22. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-22-000480 · form4-01112022_050141.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-005866 · form4-12142021_011252.xml · derivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,540

Underlying: Common Stock · 5,251 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-21-005866 · form4-12142021_011252.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,458

F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F3 · price: The weighted average sale price for the transaction reported was $10.39, and the range of prices were between $10.18 and $11.11. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-21-005866 · form4-12142021_011252.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 668 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.

SEC source: 0001415889-21-005860 · form4-12142021_011237.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 582,901

F1 · price: T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · balance_after: Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.

SEC source: 0001193805-21-001684 · e621128_4-olma.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 471,350

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.